London, England, United Kingdom
UCL medical student with a strong background in management and a clear interest in healthcare management and investment banking. Alongside my clinical training, I have gained experience across finance and strategy-focused roles, developing a solid grounding in commercial analysis. I have also held leadership positions in various societies and organised large-scale undergraduate medical conferences, giving me hands-on experience in stakeholder management, budgeting, and execution. I am particularly interested in roles at the intersection of healthcare, strategy, and finance.
• Executed buy-side M&A tax due diligence on a £100m revenue target with 3 UK legal entities, analysed three years of statutory accounts and tax computations, identified key corporate tax and transfer pricing risks, and produced a red-flag report with mitigations that directly influenced valuation adjustments and share purchase agreement terms. • Analysed share-based payments for a TMT client under IFRS 2 and HMRC guidance, reconciled book-to-tax and deferred tax differences, advised on corrective filings and disclosures, and highlighted implications for adjusted EBITDA and diluted share count, enabling more accurate deal pricing. • Scheduled, attended, and documented cross-border client meetings across multiple service lines and regions, preparing agendas and minutes, tracking actions, and liaising with stakeholders under tight deadlines.
• Executed daily independent price verification of FX options for the macro trading desk, collaborating with traders to validate marks and producing reports that supported accurate profit and loss reporting and asset remarking. • Conducted a comprehensive financial analysis of an external party to assess the bank’s £158m counterparty exposure, identifying risks and opportunities that informed senior leadership decisions and supported actions reducing exposure by £50m. • Created a weekly macro-markets newsletter for around 30 stakeholders including senior leaders, distilling rates, FX and commodities moves into trade and risk implications.